Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic

References

• Rizvi S, Khan SA, Hallemeier CL, et al. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15(2):95–111.
   PubMed Web of Science ®Google Scholar
• Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383(9935):2168–2179.
   PubMed Web of Science ®Google Scholar
• Banales JM, Cardinale V, Carpino G, et al. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13:261–280.
   PubMed Web of Science ®Google Scholar
• Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557–588.
   PubMed Web of Science ®Google Scholar
• Nakanuma Y, Kakuda Y. Pathologic classification of cholangiocarcinoma: new concepts. Best Pract Res Clin Gastroenterol. 2015;29(2):277–293.
   PubMed Web of Science ®Google Scholar
• Cardinale V, Wang Y, Carpino G, et al. Mucin-producing cholangiocarcinoma might derive from biliary tree stem/progenitor cells located in peribiliary glands. Hepatology. 2012;55(6):2041–2042.
   PubMed Web of Science ®Google Scholar
• Carpino G, Cardinale V, Folseraas T, et al. Neoplastic transformation of the peribiliary stem cell niche in cholangiocarcinoma arisen in primary sclerosing Cholangitis. Hepatology. 2019;69(2):622–638.
   PubMed Web of Science ®Google Scholar
• Komuta M, Spee B, Vander Borght S, et al. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology. 2008;47(5):1544–1556.
   PubMed Web of Science ®Google Scholar
• Marin JJG, Lozano E, Briz O, et al. Molecular bases of chemoresistance in cholangiocarcinoma. Curr Drug Targets. 2017;18(8):889–900.
   PubMed Web of Science ®Google Scholar
• DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007;245(5):755–762.
   PubMed Web of Science ®Google Scholar
• Fitzmaurice C, Abate D, Abbasi N, et al.; Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol. 2019;5:1749–1768.
   PubMed Web of Science ®Google Scholar
• Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology. 2011;54(1):173–184.
   PubMed Web of Science ®Google Scholar
• Chapman MH, Webster GJM, Bannoo S, et al. Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience. Eur J Gastroenterol Hepatol. 2012;24(9):1051–1058.
   PubMed Web of Science ®Google Scholar
• He X-D, Wang L, Liu W, et al. The risk of carcinogenesis in congenital choledochal cyst patients: an analysis of 214 cases. Ann Hepatol. 2014;13(6):819–826.
   PubMed Web of Science ®Google Scholar
• Forner A, Vidili G, Rengo M, et al. Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver Int. 2019;39(S1):98–107.
   PubMed Web of Science ®Google Scholar
• Oliveira IS, Kilcoyne A, Everett JM, et al. Cholangiocarcinoma: classification, diagnosis, staging, imaging features, and management. Abdom Radiol. 2017;42(6):1637–1649.
   PubMed Web of Science ®Google Scholar
• Tamada K, Ushio J, Sugano K. Endoscopic diagnosis of extrahepatic bile duct carcinoma: advances and current limitations. World J Clin Oncol. 2011;2(5):203–216.
   PubMedGoogle Scholar
• Rizvi S, Eaton J, Yang JD, et al. Emerging technologies for the diagnosis of perihilar cholangiocarcinoma. Semin Liver Dis. 2018;38(2):160–169.
   PubMed Web of Science ®Google Scholar
• Wannhoff A, Gotthardt DN. Recent developments in the research on biomarkers of cholangiocarcinoma in primary sclerosing cholangitis. Clin Res Hepatol Gastroenterol. 2019;43(3):236–243.
   PubMed Web of Science ®Google Scholar
• Arbelaiz A, Azkargorta M, Krawczyk M, et al. Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2017;66(4):1125–1143.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Yan I, Wen H-J, et al. microRNAs in liver disease: from diagnostics to therapeutics. Clin Biochem. 2013;46(10–11):946–952.
   PubMed Web of Science ®Google Scholar
• Dudley JC, Zheng Z, McDonald T, et al. Next-Generation sequencing and fluorescence in situ hybridization have comparable performance characteristics in the analysis of pancreaticobiliary brushings for malignancy. J Mol Diagn. 2016;18(1):124–130.
   PubMed Web of Science ®Google Scholar
• Severino V, Dumonceau J-M, Delhaye M, et al. Extracellular vesicles in bile as markers of malignant biliary stenoses. Gastroenterology. 2017;153(2). 10.1053/j.gastro.2017.04.043.
   PubMed Web of Science ®Google Scholar
• Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17:223–238.
   PubMed Web of Science ®Google Scholar
• Yang JD, Yab TC, Taylor WR, et al. Detection of cholangiocarcinoma by assay of methylated dna markers in plasma. Gastroenterology. 2017;152(5):S1041–2.
   Web of Science ®Google Scholar
• Macias RIR, Muñoz-Bellvís L, Sánchez-Martín A, et al. A novel serum metabolomic profile for the differential diagnosis of distal cholangiocarcinoma and pancreatic ductal adenocarcinoma. Cancers (Basel). 2020;12(6):1433.
   Web of Science ®Google Scholar
• Poruk KE, Pawlik TM, Weiss MJ. Perioperative management of hilar cholangiocarcinoma. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2015;19(10):1889–1899.
   Google Scholar
• Mansour JC, Aloia TA, Crane CH, et al. Hilar cholangiocarcinoma: expert consensus statement. HPB. 2015;17(8):691–699.
   PubMed Web of Science ®Google Scholar
• Nuzzo G, Giuliante F, Ardito F, et al. Improvement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients. Arch Surg. 2012;147(1):26–34.
   PubMedGoogle Scholar
• KwonHJ, Kim SG, Chun JM, et al. Prognostic factors in patients with middle and distal bile duct cancers. World J Gastroenterol. 2014;20(21):6658–6665.
   PubMed Web of Science ®Google Scholar
• Khan AS, Dageforde LA. Cholangiocarcinoma. Surg Clin North Am. 2019;99(2):315–335.
   PubMed Web of Science ®Google Scholar
• Goldaracena N, Gorgen A, Sapisochin G. Current status of liver transplantation for cholangiocarcinoma. Liver Transpl. 2018;24(2):294–303.
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Haddock MG, Alberts SR, et al. Transplantation for hilar cholangiocarcinoma. Liver Transpl. 2004;10(S10):S65–68.
   PubMed Web of Science ®Google Scholar
• Gores GJ, Darwish Murad S, Heimbach JK, et al. Liver transplantation for perihilar cholangiocarcinoma. Dig Dis. 2013;31(1):126–129.
   PubMed Web of Science ®Google Scholar
• Zamora-Valdes D, Heimbach JK. Liver transplant for cholangiocarcinoma. Gastroenterol Clin North Am. 2018;47(2):267–280.
   PubMed Web of Science ®Google Scholar
• Valle JW, Furuse J, Jitlal M, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol. 2014;25(2):391–398.
   PubMed Web of Science ®Google Scholar
• Marin JJG, Prete MG, Lamarca A, et al. Current and novel therapeutic opportunities for systemic therapy in biliary cancer. Br J Cancer. 2020;123(7):1047–1059.
   PubMed Web of Science ®Google Scholar
• Andersen JB, Thorgeirsson SS. Genetic profiling of intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol. 2012;28(3):266–272.
   PubMed Web of Science ®Google Scholar
• Montal R, Sia D, Montironi C, et al. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. J Hepatol. 73(2): 315–327. 2020.
   PubMed Web of Science ®Google Scholar
• Fouassier L, Marzioni M, Afonso MB, et al. Signalling networks in cholangiocarcinoma: molecular pathogenesis, targeted therapies and drug resistance. Liver Int. 2019;39(S1):43–62.
   PubMed Web of Science ®Google Scholar
• Clements O, Eliahoo J, Kim JU, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Hepatol. 2020;72(1):95–103.
   PubMed Web of Science ®Google Scholar
• Petrick JL, Yang B, Altekruse SF, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based study in SEER-Medicare. PloS One. 2017;12(10):e0186643.
   PubMed Web of Science ®Google Scholar
• Shin H-R, Oh J-K, Masuyer E, et al. Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci. 2010;101(3):579–585.
   PubMed Web of Science ®Google Scholar
• Wongjarupong N, Assavapongpaiboon B, Susantitaphong P, et al. Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis. BMC Gastroenterol. 2017;17(1):149.
   PubMed Web of Science ®Google Scholar
• Jing W, Jin G, Zhou X, et al. Diabetes mellitus and increased risk of cholangiocarcinoma: a meta-analysis. Eur J Cancer Prev. 2012;21(1):24–31.
   PubMed Web of Science ®Google Scholar
• Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47(9):1003–1010.
   PubMed Web of Science ®Google Scholar
• Putra J, de Abreu FB, Peterson JD, et al. Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing. Exp Mol Pathol. 2015;99(2):240–244.
   PubMed Web of Science ®Google Scholar
• Lowery MA, Ptashkin R, Jordan E, et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for Intervention. Clin Cancer Res. 2018;24(17):4154–4161.
   PubMed Web of Science ®Google Scholar
• Aoki S, Mizuma M, Takahashi Y, et al. Aberrant activation of Notch signaling in extrahepatic cholangiocarcinoma: clinicopathological features and therapeutic potential for cancer stem cell-like properties. BMC Cancer. 2016;07(1):854.
   Web of Science ®Google Scholar
• Gradilone SA, Radtke BN, Bogert PS, et al. HDAC6 inhibition restores ciliary expression and decreases tumor growth. Cancer Res. 2013;73(7):2259–2270.
   PubMed Web of Science ®Google Scholar
• Valle JW, Lamarca A, Goyal L, et al. New horizons for precision medicine in biliary tract cancers. Cancer Discov. 7(9): 943–962. 2017.
   PubMed Web of Science ®Google Scholar
• Andersen JB, Spee B, Blechacz BR, et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology. 2012;142(4). 10.1053/j.gastro.2011.12.005.
   PubMed Web of Science ®Google Scholar
• Nakazawa K, Dobashi Y, Suzuki S, et al. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol. 2005;206(3):356–365.
   PubMed Web of Science ®Google Scholar
• Yoshikawa D, Ojima H, Iwasaki M, et al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer. 2008;98(2):418–425.
   PubMed Web of Science ®Google Scholar
• Clapéron A, Mergey M, Nguyen Ho-Bouldoires TH, et al. EGF/EGFR axis contributes to the progression of cholangiocarcinoma through the induction of an epithelial-mesenchymal transition. J Hepatol. 2014;61(2):325–332.
   PubMed Web of Science ®Google Scholar
• Pignochino Y, Sarotto I, Peraldo-Neia C, et al. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer. 2010;10(1):631.
   PubMed Web of Science ®Google Scholar
• Zheng J, Zhu Y-M. Expression of c-erbB-2 proto-oncogene in extrahepatic cholangiocarcinoma and its clinical significance. Hepatobiliary Pancreat Dis Int. 2007;6(4):412–415.
   PubMed Web of Science ®Google Scholar
• Sugihara T, Isomoto H, Gores G, et al. YAP and the Hippo pathway in cholangiocarcinoma. J Gastroenterol. 2019;54(6):485–491.
   PubMed Web of Science ®Google Scholar
• Chakravarty D, Gao J, Phillips SM, et al. OncoKB: a precision oncology knowledge base. JCO Precis Oncol. 2017;2017: PO.17.00011.
   Google Scholar
• Lamarca A, Kapacee Z, Breeze M, et al. Molecular profiling in daily clinical practice: practicalities in advanced cholangiocarcinoma and other biliary tract cancers. J Clin Med. 2020;9(9):2854.
   Web of Science ®Google Scholar
• Wiggers JK, Ruys AT, Groot Koerkamp B, et al. Differences in immunohistochemical biomarkers between intra- and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2014;29(8):1582–1594.
   PubMed Web of Science ®Google Scholar
• Guedj N, Zhan Q, Perigny M, et al. Comparative protein expression profiles of hilar and peripheral hepatic cholangiocarcinomas. J Hepatol. 2009;51(1):93–101.
   PubMed Web of Science ®Google Scholar
• Sun R, Liu Z, Qiu B, et al. Annexin10 promotes extrahepatic cholangiocarcinoma metastasis by facilitating EMT via PLA2G4A/PGE2/STAT3 pathway. EBioMedicine. 2019;47:142–155.
   PubMed Web of Science ®Google Scholar
• Wang J, Wang X, Xie S, et al. p53 status and its prognostic role in extrahepatic bile duct cancer: a meta-analysis of published studies. Dig Dis Sci. 2011;56(3):655–662.
   PubMed Web of Science ®Google Scholar
• Ishida K, Osakabe M, Eizuka M, et al. The expression of gastrointestinal differentiation markers in extrahepatic cholangiocarcinoma: clinicopathological significance based on tumor location. Hum Pathol. 2019;92:91–100.
   PubMed Web of Science ®Google Scholar
• Fabris L, Cadamuro M, Moserle L, et al. Nuclear expression of S100A4 calcium-binding protein increases cholangiocarcinoma invasiveness and metastasization. Hepatology. 2011;54(3):890–899.
   PubMed Web of Science ®Google Scholar
• Cadamuro M, Spagnuolo G, Sambado L, et al. Low-Dose paclitaxel reduces s100a4 nuclear import to inhibit invasion and hematogenous metastasis of Cholangiocarcinoma. Cancer Res. 2016;76(16):4775–4784.
   PubMed Web of Science ®Google Scholar
• Lee JS, Choi HJ, Baek SH. Sumoylation and Its Contribution to Cancer. Adv Exp Med Biol. 2017;963:283–298.
   PubMed Web of Science ®Google Scholar
• Kawamata F, Kamachi H, Einama T, et al. Intracellular localization of mesothelin predicts patient prognosis of extrahepatic bile duct cancer. Int J Oncol. 2012;41(6):2109–2118.
   PubMed Web of Science ®Google Scholar
• Li L, Masica D, Ishida M, et al. Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis. Hepatology. 2014;60(3):896–907.
   PubMed Web of Science ®Google Scholar
• Loeffler MA, Hu J, Kirchner M, et al. miRNA profiling of biliary intraepithelial neoplasia reveals stepwise tumorigenesis in distal cholangiocarcinoma via themiR451a/ATF2axis. J Pathol. 2020;252(3):239–251.
   PubMed Web of Science ®Google Scholar
• Sawada R, Ku Y, Akita M, et al. Interleukin-33 overexpression reflects less aggressive tumour features in large-duct type cholangiocarcinomas. Histopathology. 2018;73(2):259–272.
   PubMed Web of Science ®Google Scholar
• Arnoletti JP, Fanaian N, RezaJ, etal. Pancreatic and bile duct cancer circulating tumor cells (CTC) form immune-resistant multi-cell type clusters in the portal venous circulation. Cancer Biol Ther. 2018;19(10):887–897.
   PubMed Web of Science ®Google Scholar
• Yang JD, Campion MB, Liu MC, et al. Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma. Hepatology. 2016;63(1):148–158.
   PubMed Web of Science ®Google Scholar
• Banales JM, Iñarrairaegui M, Arbelaiz A, et al. Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma, and primary sclerosing Cholangitis. Hepatology. 2019;70(2):547–562.
   PubMed Web of Science ®Google Scholar
• Liang Q, Liu H, Zhang T, et al. Serum metabolomics uncovering specific metabolite signatures of intra- and extrahepatic cholangiocarcinoma. Mol Biosyst. 2016;12(2):334–340.
   PubMed Web of Science ®Google Scholar
• Home - ClinicalTrials.gov .. cited https://clinicaltrials.gov/
   Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 Blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–2520.
   PubMed Web of Science ®Google Scholar
• Piha-Paul SA, Oh D-Y, Ueno M, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE028 studies. Int J Cancer. 2020;147(8):2190–2198.
   PubMed Web of Science ®Google Scholar
• Lozano E, Sanchez-Vicente L, Monte MJ, et al. Cocarcinogenic effects of intrahepatic bile acid accumulation in cholangiocarcinoma development. Mol Cancer Res. 2014;12(1):91–100.
   PubMed Web of Science ®Google Scholar
• Erice O, Labiano I, Arbelaiz A, et al. Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression. Biochim Biophys Acta Mol Basis Dis. 2018;1864(4):1335–1344.
   PubMed Web of Science ®Google Scholar
• Britten CD, Garrett-Mayer E, Chin SH, et al. A phase i study of ABC294640, a First-in-class sphingosine kinase-2 Inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2017;23(16):4642–4650.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Tempero MA, Sigal D, et al. Randomized Phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma. J Clin Oncol. 2020;38(27):3185–3194.
   PubMed Web of Science ®Google Scholar
• El Khatib M, Kalnytska A, Palagani V, et al. Inhibition of hedgehog signaling attenuates carcinogenesis in vitro and increases necrosis of cholangiocellular carcinoma. Hepatology. 2013;57(3):1035–1045..
   PubMed Web of Science ®Google Scholar
• Riedlinger D, Bahra M, Boas-Knoop S, et al. Hedgehog pathway as a potential treatment target in human cholangiocarcinoma. J Hepato-Biliary-Pancreat Sci. 2014;21(8):607–615.
   PubMed Web of Science ®Google Scholar
• Fingas CD, Mertens JC, Razumilava N, et al. Polo-like kinase 2 is a mediator of hedgehog survival signaling in cholangiocarcinoma. Hepatology. 2013;58(4):1362–1374.
   PubMed Web of Science ®Google Scholar
• Yarlagadda B, Kamatham V, Ritter A, et al. Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma. NPJ Precis Oncol. 2019;3(1):19.
   PubMed Web of Science ®Google Scholar
• Subbiah V, Lassen U, Élez E, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020;21(9):1234–1243.
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–413.
   PubMed Web of Science ®Google Scholar
• O’Neill BH, Wallmark J, Lorente D, et al. Pembrolizumab (MK-3475) for patients (pts) with advanced colorectal carcinoma (CRC): preliminary results from KEYNOTE-028. EJC. 2015;51:S103.
   Google Scholar
• Kim RD, Chung V, Alese OB, et al. A Phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer. JAMA Oncol. 2020;6:888–894.
   PubMed Web of Science ®Google Scholar
• Pellino A, Loupakis F, Cadamuro M, et al. Precision medicine in cholangiocarcinoma. Transl Gastroenterol Hepatol. 2018;3:40.
   PubMed Web of Science ®Google Scholar
• Lee MKC, Loree JM. Current and emerging biomarkers in metastatic colorectal cancer. Curr Oncol. 2019;26(Suppl 1):S7–15.
   PubMed Web of Science ®Google Scholar
• de Mello RA, Neves NM, Tadokoro H, et al. New target therapies in advanced non-small cell lung cancer: A review of the literature and future perspectives. J Clin Med. 2020;9(11):E3543.
   PubMed Web of Science ®Google Scholar
• Nakai K, Hung M-C YH. A perspective on anti-EGFR therapies targeting triple-negative breast cancer. Am J Cancer Res. 2016;6(8):1609–1623.
   PubMed Web of Science ®Google Scholar
• Adashek JJ, Arroyo-Martinez Y, Menta AK, et al. Therapeutic Implications of Epidermal Growth Factor Receptor (EGFR) in the treatment of metastatic gastric/GEJ Cancer. Front Oncol. 2020;10:1312.
   PubMed Web of Science ®Google Scholar
• Sia D, Losic B, Moeini A, et al. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat Commun. 2015;6(1):6087 .
   PubMed Web of Science ®Google Scholar
• Farshidfar F, Zheng S, Gingras M-C, et al. Integrative genomic analysis of cholangiocarcinoma identifies distinct idh-mutant molecular profiles. Cell Rep. 2017;18(11):2780–2794.
   PubMed Web of Science ®Google Scholar
• Lamarca A, Barriuso J, McNamara MG, et al. Molecular targeted therapies: ready for “prime time” in biliary tract cancer. J Hepatol. 2020;73(1):170–185.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020 May;21(5):671–684.
   PubMed Web of Science ®Google Scholar
• Romero D. Benefit from pemigatinib in cholangiocarcinoma. Nat Rev Clin Oncol. 2020 Jun;17(6):337.
   PubMed Web of Science ®Google Scholar
• Merz V, Zecchetto C, Melisi D. Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma. Future Oncol. 2020; Epub ahead of print.10.2217/fon-2020-0726
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020 Jun;21(6):796–807.
   PubMed Web of Science ®Google Scholar
• Cadamuro M, Brivio S, Stecca T, et al. Animal models of cholangiocarcinoma: what they teach us about the human disease. Clin Res Hepatol Gastroenterol. 2018 Oct;42(5):403–415.
   PubMed Web of Science ®Google Scholar
• Aung KL, Fischer SE, Denroche RE, et al. Genomics-Driven precision medicine for advanced pancreatic cancer: Early results from the COMPASS Trial. Clin Cancer Res. 2018;24(6):1344–1354.
   PubMed Web of Science ®Google Scholar
• Leone F, Marino D, Cereda S, et al. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: a randomized phase 2 trial (Vecti-BIL study). Cancer. 2016;122(4):574–581.
   PubMed Web of Science ®Google Scholar
• Mertens JC, Fingas CD, Christensen JD, et al. Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma. Cancer Res. 2013;73(2):897–907.
   PubMed Web of Science ®Google Scholar
• Cadamuro M, Brivio S, Mertens J, et al. Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma. J Hepatol. 2019;70(4):700–709.
   PubMed Web of Science ®Google Scholar
• Fingas CD, Bronk SF, Werneburg NW, et al. Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells. Hepatology. 2011;54(6):2076–2088.
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905.
   PubMed Web of Science ®Google Scholar
• Galdy S, Lamarca A, McNamara MG, et al. HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target? Cancer Metastasis Rev. 2017;36(1):141–157.
   PubMed Web of Science ®Google Scholar
• Piersma B, Hayward MK, Weaver VM. Fibrosis and cancer: a strained relationship. Biochim Biophys Acta Rev Cancer. 2020 Apr;1873(2):188356.
   PubMed Web of Science ®Google Scholar
• Pandol S, Edderkaoui M, Gukovsky I, et al. Desmoplasia of pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol. 2009 Nov;7(11):S44–7.
   PubMed Web of Science ®Google Scholar
• Rhim AD, Oberstein PE, Thomas DH, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014 Jun 16;25(6):735–747.
   PubMed Web of Science ®Google Scholar
• Özdemir BC, Pentcheva-Hoang T, Carstens JL, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014 Jun 16;25(6):719–734.
   PubMed Web of Science ®Google Scholar
• Marin JJG, Lozano E, Herraez E, et al. Chemoresistance and chemosensitization in cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4):1444–1453.
   PubMed Web of Science ®Google Scholar
• Wu HJ, Chu PY. Role of cancer stem cells in cholangiocarcinoma and therapeutic implications. Int J Mol Sci. 2019 Aug 25;20(17):4154.
   PubMed Web of Science ®Google Scholar
• ENS-CCA. Citedhttp://www.enscca.org/.
   Google Scholar